Drug Profile
Research programme: bispecific antibody therapeutics - Merus
Alternative Names: MCLA-114; MCLA-122; MCLA-134Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Merus
- Developer Merus; ProBioGen
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen modulators; Epidermal growth factor modulators; Epidermal growth factor receptor antagonists; ERBB-3 receptor modulators; G protein-coupled receptor modulators; Programmed cell death-1 receptor modulators; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Colorectal cancer; Multiple myeloma; Solid tumours
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Colorectal cancer in USA (Parenteral)
- 25 Aug 2023 Discontinued - Preclinical for Solid tumours in Netherlands (Parenteral)
- 25 Aug 2023 Discontinued for Multiple myeloma in Netherlands (Parenteral)